Canaccord: SAGE Therapeutics Now Worth $85/Share On 'Higher Probability Of Success' For Drug
May 21, 2015 at 13:02 PM EDT
In a report published Thursday, Canaccord Genuity analysts maintained a Buy rating on SAGE Therapeutics Inc (NASDAQ: SAGE), while ...